PMCHL2
Putative pro-MCH-like protein 2
Also known as: MCHL2_HUMAN
Protein identityUniProt · HPA
OverviewNCBI Gene
No narrative summary is available for PMCHL2 in this catalog release; identity and structured annotations are shown without generated factual claims.
Canonical amino-acid sequenceUniProt
86 residues, UniProt reviewed canonical sequence.
>Q9BQD1|PMCHL2
1 MLSQKTKKKH NFLNHGLSLN LVIKPYLALE GSVAFPAENG VQDTESTLEK RETGDEENSA
61 KFPIGRRDFD TLRCMLGRVY QRCWQVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PMCHL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.69
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PMCHL2 as an antibody target. Whether an autoantibody or antibody against PMCHL2 could matter depends on whether native PMCHL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PMCHL2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PMCHL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...